Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 Operating Income

As of the most recent data (June 2026), HROWM shows a operating income of $-2.7M. That compares with $14M in the prior-year period — down 119.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, HROWM's operating income is now $-2.7M (was $14M) — a 119.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 is outperforming or lagging.

Tracking HROWM's operating income over time shows whether Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 is scaling, shrinking, or reshaping that part of the business. The current reading is $-2.7M That compares with $14M in the prior-year period — down 119.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-2.7M) with ownership activity and broader fundamentals.

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's operating income is $-2.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.